What is Flubromazolam?
Flubromazolam is a research chemical from the chemical class of TriazoloBenzodiazepine, this is a benzodiazepine derivative. Chemical Researchers that have conducted experiments with Flubromazolam have shown results of sedation, amnesia, and muscle relaxation, it is an extremely potent benzodiazepine, so these results in experiments are prominent with as little as 0.25mg being used.
When doing any research with Flubromazolam caution must be taken to cover exposed parts of your skin by using the correct personal protective equipment – Gloves, Mask, Overalls these are all essential.
Always store in a cool, dry place for maximum shelf-life. This product is intended for forensic and research applications only. It is therefore NOT intended for human consumption or in-vivo testing of any kind on animals or any living organism.
Chemistry of Flubromazolam
Introduction of Flubromazolam
Being a research chemical the Flubromazolam belongs to the benzodiazepine class and is a novel synthetic-depressant substance. When administrated, it produces the muscle relaxant, sedative, anxiolytic and also memory suppressing effects. With an unusually long duration of 18 hours it is incredibly potent (active in the microgram range).
Benefits of Flubromazolam
Flubromazolam is very well known for the short-term treatment of insomnia, anxiety, acute seizures and the sedation of the hospitalized patients. Currently, this research chemical is exclusively sold online, by the research chemical vendors. This has not been formally studied but usually, it is used as a recreational psychoactive substance but is potentially dangerous.
Chemistry of Flubromazolam
Flubromazolam is a research chemical of the benzodiazepine class and on its core benzodiazepine skeleton, it is named for the bromine, fluorine and the triazole substitutions. It features a 1,4 diazepine ring that is fused to the substituted benzene ring.
At R7 the bromine is bound to this bicyclic structure. Also, at R5 a fluorine-substituted phenyl ring is bound to its structure. Additionally, Flubromazolam features a methylated triazole ring that is fused to the structure and it is incorporating the R1 and the R2 of its diazepine ring. This research chemical belongs to a class of benzodiazepines in which the triazole ring is fused and are known as triazolobenzodiazepines. These are easily distinguished by using the suffix which is “-zolam”.
Pharmacology of Flubromazolam
By binding to the benzodiazepine receptor site, a variety of effects are produced by Benzodiazepines. The modulation of this substance results in the sedation (or calming effects) of the flubromazepam on the nervous system as this site has been best set within the brain. In part of entirely, through the binding to the voltage-dependent-sodium channels except of benzodiazepine receptors the benzodiazepines are able to get their anticonvulsant properties.
Subjective effects of Flubromazolam
By some users that have experienced Flubromazolam, it is suggested that this is one of the most euphoric benzodiazepines. This research chemical is famous for its sedative effects and also the anxiolytic and hypothetic effects. It is cautioned that the sudden discontinuation of the benzodiazepines can be potentially very dangerous and can life-threatening for the people that are using it regularly.
Formal Name: 8-bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
CAS Number: 612526-40-6
Molecular Formula: C17H12BrFN4
Formula Weight: 371.2
Formulation: A neat solid
InChI Code: InChI=1S/C17H12BrFN4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3
InChI Key: VXGSZBZQCBNUIP-UHFFFAOYSA-N
Warning – this product is not for human or veterinary use.
Buy flubromazolam | 100% Good quality
Flubromazolam (JYI-73)  is a triazolobenzodiazepine (TBZD), which are benzodiazepine (BZD) derivatives. Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg. Life-threatening adverse reactions have been observed at doses of only 3 mg of flubromazolam.
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||371.213 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Flubromazolam is a potent triazole benzodiazepine with moderately long-lasting central nervous system–depressant effects relative to other benzodiazepines such as commonly prescribed diazepam. Flubromazolam has been studied in the living. However, there are no published reports including measured drug concentrations in post-mortem cases. We report five cases in which flubromazolam was detected in a systematic screen using high-resolution mass spectrometry and then quantified in femoral blood.
In none of the five cases was the cause of death directly attributed to flubromazolam toxicity, as there was a variety of both sedative and stimulant drugs also present. However, it is important that the drug concentrations that were measured are made available for future post-mortem forensic interpretation.
Designer products, a term referring to analogs of known chemical compounds with no established medical use, represent an easily accessible alternative to prescription-only products. During the past decade, designer benzodiazepines have become widely available on the online forums.
Although these agents offer individuals an inexpensive and accessible alternative to prescription-only products, they are not without risk. Because of the lack of federally enforced quality standards, these designer products come with an intrinsic risk of unpredictable and potentially toxic adverse effects. This article presents a 36-year-old male with prolonged bradycardia resulting from the use of flubromazolam, a designer benzodiazepine purchased from the Internet.
A PubMed search was conducted for flubromazolam, designer benzodiazepine, and flumazenil. This article will summarize the available literature regarding flubromazolam and the role of flumazenil in managing these overdoses.
Benzodiazepines are a popular class of anxiolytics often implicated in both intentional and unintentional overdoses.1 The American Association of Poison Control Centers’ National Poison Data System includes benzodiazepines within the sedative/hypnotic category.
According to their most recent report,1 this was the second most common category of substances involved in adult overdoses reported to US poison centers in 2016. Furthermore, they were implicated in the largest number of fatal overdoses that year.1 Compared with 2015, the rate of increase for sedative/hypnotic overdoses was greater than for all other substance categories.1
In addition to prescription benzodiazepines, a number of new designer benzodiazepines were introduced to the illicit drug market beginning in 2012.2 These designer products, a term referring to analogs of known chemical compounds with no established medical use, represent an easily accessible alternative to prescription-only benzodiazepines.3
Reported uses for the designer benzodiazepines include self-medicating for anxiety, reducing the symptoms of prescription benzodiazepine withdrawal, and seeking recreational intoxication.4,5 Because of their broad scope of use, the designer substances have presented an enormous challenge to both clinical and forensic toxicologists as well as policy makers.5
Flubromazolam is just one example of a designer benzodiazepine marketed on Internet shops as a research chemical.2–4 Although it is available for purchase, it is not a prescription product regulated by the US Food and Drug Administration.
Flubromazolam has yet to be classified as a controlled substance in the United States at the federal level. The only state to classify it as a Schedule I controlled substance is Virginia.4,6 Unlike the United States, European countries have federally regulated flubromazolam since 2015.
It was classified as a narcotic substance in Switzerland in 2015 and has been illegal to produce, supply, or consume in the United Kingdom since 2016.4 Prescription benzodiazepines are generally regarded as having a more favorable safety profile than their barbiturate predecessors and undergo extensive premarket testing.
Designer benzodiazepines, however, do not undergo the same safety and toxicity testing and therefore have indeterminate potency and the potential to cause unforeseen clinical manifestations (eg, uncharacteristic signs/symptoms, unintentional overdose).3
A 36-year-old male with a history of schizoaffective disorder, anxiety, posttraumatic stress disorder, opioid use disorder, and seizures presented to an inpatient psychiatric facility for worsening anxiety. His home medications included fluoxetine, clonazepam, buprenorphine, lamotrigine, tramadol, and baclofen.
To manage his anxiety, he admitted to using a “research chemical” he purchased from the Internet. He appeared lethargic and could not recall its exact name at the time of his initial interview.
He was accepted for direct admission to the psychiatric facility for the management of sedative dependence and withdrawal. The next morning, he was noted to be “nearly obtunded” and was transferred to the emergency department (ED) for the evaluation of hypotension and bradycardia that had developed throughout the night.
Upon arrival to the ED he was lethargic, but he was responsive to verbal stimuli, with a heart rate (HR) of 49 beats/min and a blood pressure of 110/64 mm Hg. When interviewed in the ED he recalled that he had purchased flubromazolam and he usually took 0.4 mg to achieve anxiolysis.
He did not experience the same relief this time, however, and believed he received a “bad batch.” Because his anxiety persisted he increased his dose to 3 to 4 mg in an effort to elicit the same effect. His last 3-mg dose was taken shortly before presenting to the psychiatric facility the previous evening.
On physical examination he was noted to have midrange pupils, active bowel sounds, supple muscle tone, and skin that was warm and dry. His laboratory evaluation was only remarkable for benzodiazepines detected in a routine urine drug screen. His electrocardiogram revealed sinus bradycardia with normal intervals.
He was treated supportively with 1 L of normal saline and was placed on continuous cardiac monitoring. Although he remained persistently bradycardic he was hemodynamically stable. Because of his known comorbidities the decision was made to not administer flumazenil. Because his HR remained in the 40s with mild hypotension, he was admitted to the intensive care unit for further monitoring.
His intensive care unit admission was uneventful and required no lifesaving interventions. Approximately 72 hours into his hospital course his vital signs returned to baseline (HR, 72 beats/min; blood pressure, 137/83 mm Hg). He was medically cleared for transfer back to the inpatient psychiatric facility thereafter for management of his sedative dependence. No further adverse events were reported.
Although they exist within a legal gray area, designer benzodiazepines are readily available for purchase on the Internet despite the limited information known about them.
A PubMed search limited to the English language and human data was conducted using the keywords flubromazolam, designer benzodiazepine, and flumazenil. Diclazepam, flubromazepam, flubromazolam, and clonazolam are some designer benzodiazepines reported in the literature.3 Powders, injectable solutions, and blotters are a few examples of the many formulations available to online consumers.3
The individual in this case reported using flubromazolam. Flubromazolam is the triazolo-analog of another designer benzodiazepine, flubromazepam, and is structurally related to the prescription triazole benzodiazepines alprazolam and triazolam.2,4
Because flubromazolam has not been extensively tested, the exact dose at which clinical effects manifest following ingestion is unknown.
On Internet forums mild anxiolytic and skeletal muscle relaxant effects have been reported with doses as low as 0.1 mg and significant sedation at doses of 0.5 mg.3–5 Flubromazolam has been described as “hard to dose” because of its unpredictable dose-response effects.5 Other clinical manifestations described in online forums include cognitive impairment, memory loss, ataxia, sleep paralysis, visual disturbances, heart palpitations, rapid onset of tolerance, and severe withdrawal lasting more than a month.5 A summary of the symptoms reported in the medical literature can be found in the Table.